NEWTON, Mass.--(BUSINESS WIRE)--Pro-Pharmaceuticals, Inc. (Amex: PRW), a developer of novel, first-in-class carbohydrate compounds today issued an update on its Phase II clinical trial for first-line treatment of chemotherapy-sensitive colorectal cancer patients and its Phase II study for first-line treatment of biliary cancer patients. Treatment for both trials may represent opportunities for Orphan Drug status approval.
